Trial Profile
A Randomized, Multi-Center, Prospective, Double Blind, Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Glibenclamide (Primary)
- Indications Stroke
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms GAMES-RP
- Sponsors Biogen
- 20 Sep 2019 Results published in the Stroke
- 08 Feb 2019 Results assessing the effect of Glibenclamide on Water Uptake and Mass Effect in Large Hemispheric Infarction, presented at the International Stroke Conference 2019
- 22 May 2018 Results (n=86) efficacy and tolerability of glibenclamide [CIRARA; Remedy Pharmaceuticals] in patients with a severe anterior circulation ischaemic stroke who are likely to develop malignant oedema, were published in the Stroke.